Abbonarsi

The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: A prospective, randomized, double-blind, placebo-controlled trial - 14/05/14

Doi : 10.1016/j.jaad.2014.01.898 
Sherief R. Janmohamed, MD a, d, Arnold P. Oranje, MD, PhD a, d, e, , Arjan C. Devillers, MD, PhD e, Dimitris Rizopoulos, PhD c, Marinus C.G. van Praag, MD, PhD f, Dirk Van Gysel, MD, PhD g, Marleen Goeteyn, MD h, Flora B. de Waard-van der Spek, MD, PhD b, d
a Department of Pediatrics, Division of Pediatric Dermatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands 
b Department of Dermatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands 
c Department of Biostatistics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands 
d KinderHaven, Havenziekenhuis, Rotterdam, The Netherlands 
e Department of Dermatology, Maasstad Ziekenhuis, Rotterdam, The Netherlands 
f Department of Dermatology, Sint Franciscus Gasthuis, Rotterdam, The Netherlands 
g Department of Pediatrics, OLV Hospital, Aalst, Belgium 
h Department of Dermatology, AZ Sint-Jan Brugge Oostende AV, Campus Brugge, Brugge, Belgium 

Reprint requests: Arnold P. Oranje, MD, PhD, Departments of Dermatology, Maasstad Hospital Rotterdam and Dermicis Alkmaar, PO Box 8176, 3009 AD, Rotterdam, The Netherlands.

Abstract

Background

Wet-wrap treatment (WWT) has been advocated as a relatively effective treatment in children with severe atopic dermatitis (AD). WWT often serves as crisis intervention for AD.

Objectives

We sought to evaluate the use of WWT with diluted corticosteroids in comparison with emollient in children with severe AD during 4 weeks in a proactive schedule during which the frequency of corticosteroid applications was tapered.

Methods

A randomized, double-blind, placebo-controlled study was performed in children aged 6 months to 10 years with severe AD (objective SCORAD at least 40 ± 5), comparing WWT with diluted corticosteroids (1:3 mometasone furoate 0.1% ointment and for the face 1:19 mometasone furoate 0.1% ointment under a mask) with emollient (petrolatum 20% in cetomacrogol cream). The primary outcome was improvement of the objective SCORAD; secondary outcomes included Patient-Oriented Eczema Measure and quality-of-life index.

Results

WWT with diluted corticosteroids acted faster and was more efficacious than WWT with emollients. Best results were obtained in age groups 6 to 9 years and 0 to 3 years. The difference in efficacy evaluated by objective SCORAD was significant at all measuring points. This also applied to the quality-of-life index.

Limitations

The study group was relatively small.

Conclusions

WWT for severe AD is an effective therapy option for at least a period of 4 weeks.

Il testo completo di questo articolo è disponibile in PDF.

Key words : atopic dermatitis, diluted corticosteroids, emollients, eczema, long-term-intervention, wet-wrap treatment

Abbreviations used : AD, HPA, POEM, QOL, WWT


Mappa


 Sherief R. Janmohamed and Arnold P. Oranje contributed equally to this study.
 Nonrestricted funds were received from Schering-Plough BV, Fagron, Astellas, Molnlycke, Aardbeesie Project (www.aardbeesie.nl), and Foundation for Pediatric Dermatology Rotterdam (www.pediatric-dermatology.com).
 Conflicts of interest: None declared.


© 2014  American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 70 - N° 6

P. 1076-1082 - giugno 2014 Ritorno al numero
Articolo precedente Articolo precedente
  • Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis
  • Gunnthorunn Sigurdardottir, Anna-Karin Ekman, Mona Ståhle, Cecilia Bivik, Charlotta Enerbäck
| Articolo seguente Articolo seguente
  • Duration of efficacy increases with the repetition of botulinum toxin A injections in primary palmar hyperhidrosis: A study of 28 patients
  • Marie Lecouflet, Christophe Leux, Marion Fenot, Philippe Célerier, Hervé Maillard

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.